Theratechnologies Provides Update on EGRIFTA SV® Supply

Rubriques :

MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that a shortage of EGRIFTA SV® (tesamorelin for injection) will occur at the patient level in mid-January 2025, following a voluntary shutdown of the […]

XORTX Announces Change of Auditor

financialpost.com - 17/Jan 22:01

CALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV:...

Yellow Pages announces first winner of its 2025 directory cover competition

financialpost.com - 14/Jan 19:37

MONTREAL, Jan. 14, 2025 (GLOBE NEWSWIRE) — Yellow Pages Limited (TSX: Y) (“Yellow Pages” or the “Company”), a leading Canadian digital...

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

drugs.com - 21/Jan 18:01

WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on...

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

drugs.com - 21/Jan 18:01

WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on...

Stealth BioTherapeutics Announces PDUFA Action Date Extension for Elamipretide to Treat Patients with Barth Syndrome

drugs.com - 23/Jan 18:01

NEEDHAM, Mass., Jan. 23, 2025 /PRNewswire/ — Stealth BioTherapeutics Inc. (the “Company” or “Stealth”), a clinical-stage...

J&J is in talks to buy Biotech Intra-Cellular

businessmirror.com.ph - 13/Jan 12:41

Johnson & Johnson (J&J) is in talks to acquire Intra-Cellular Therapies Inc., a biopharmaceutical company focused on treatments for central...

Colliers to announce fourth quarter and full year results on February 6, 2025

reitreport.ca - 17/Jan 14:30

TORONTO, Jan. 17, 2025 (GLOBE NEWSWIRE) — Colliers International Group Inc. (TSX & NASDAQ: CIGI) (“Colliers” or the “Company”) today...

Timbercreek Financial Declares January 2025 Dividend

reitreport.ca - 23/Jan 22:00

TORONTO, Jan. 23, 2025 (GLOBE NEWSWIRE) — Timbercreek Financial (TSX: TF) (the “Company”) is pleased to announce that it has declared a monthly...

Corporate Update

financialpost.com - 17/Jan 22:47

MONTREAL, Jan. 17, 2025 (GLOBE NEWSWIRE) — Management of Dios Exploration (“Dios”) (TSX-V: DOS) is pleased to report Mr. Normand Payette,...

GenSight Biologics announces publication of 5─year outcomes for patients treated unilaterally with Lumevoq gene therapy

pharmabiz.com - 16/Jan 15:35

GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and...

Rubriques :

Theratechnologies Provides Update on EGRIFTA SV® Supply

Articles similaires

XORTX Announces Change of Auditor

Yellow Pages announces first winner of its 2025 directory cover competition

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Stealth BioTherapeutics Announces PDUFA Action Date Extension for Elamipretide to Treat Patients with Barth Syndrome

J&J is in talks to buy Biotech Intra-Cellular

Colliers to announce fourth quarter and full year results on February 6, 2025

Timbercreek Financial Declares January 2025 Dividend

Corporate Update

GenSight Biologics announces publication of 5─year outcomes for patients treated unilaterally with Lumevoq gene therapy

Les derniers communiqués